Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Efficacy and Safety Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled SPROUT Study. J of Skin 2023, 7 (6), s254. https://doi.org/10.25251/skin.7.supp.254.